BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Dupixent Discussions - ECPv6.15.19//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.dupixentdiscussions.com
X-WR-CALDESC:Events for Dupixent Discussions
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20240310T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20241103T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20250309T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20251102T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20260308T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20261101T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20270314T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20271107T070000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Denver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20240310T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20241103T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20250309T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20251102T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20260308T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20261101T080000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20240310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20241103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251103T121500
DTEND;TZID=America/New_York:20251103T124500
DTSTAMP:20260408T060921
CREATED:20250829T203315Z
LAST-MODIFIED:20250926T005501Z
UID:10000736-1762172100-1762173900@www.dupixentdiscussions.com
SUMMARY:A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Karan Lal\, DO
DESCRIPTION:This program is being held in partnership with SDPA. Please visit the link below to be taken to the registration page for this program. \nRegister \n 
URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-karan-lal-do/
LOCATION:Virtual (Zoom)
CATEGORIES:Atopic Dermatitis (AD)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Karan-Lal-DO.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20251103T121500
DTEND;TZID=America/Chicago:20251103T131500
DTSTAMP:20260408T060921
CREATED:20250829T203315Z
LAST-MODIFIED:20250924T195938Z
UID:10000737-1762172100-1762175700@www.dupixentdiscussions.com
SUMMARY:DUPIXENT@ (dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Omar Noor\, MD
DESCRIPTION:Join us for a virtual discussion with an expert speaker and an adult patient with prurigo nodularis (PN) to Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=95080527083″]
URL:https://www.dupixentdiscussions.com/event/dupixent%c2%a8-dupilumab-patient-story-followed-by-a-treatment-option-for-appropriate-patients-with-certain-skin-diseases-driven-in-part-by-type-2-inflammation-by-omar-noor-md/
LOCATION:Virtual (Zoom)
CATEGORIES:Prurigo Nodularis (PN)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Omar-Noor-MD-is4bst.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20251104T121500
DTEND;TZID=America/Denver:20251104T131500
DTSTAMP:20260408T060921
CREATED:20250829T203318Z
LAST-MODIFIED:20250919T211655Z
UID:10000738-1762258500-1762262100@www.dupixentdiscussions.com
SUMMARY:Clinical Case Discussion: A Pediatric Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age by Autumn Burnette\, MD
DESCRIPTION:Join us for a program discussing a real-world case of a pediatric patient with moderate-to-severe atopic dermatitis (AD) and a treatment option that may help appropriate patients with Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=99103141305″]
URL:https://www.dupixentdiscussions.com/event/clinical-case-discussion-a-pediatric-patient-with-uncontrolled-moderate-to-severe-atopic-dermatitis-and-a-treatment-option-for-appropriate-patients-6-months-of-age-by-autumn-burnette-md/
LOCATION:Virtual (Zoom)
CATEGORIES:Atopic Dermatitis (AD)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Autumn-Burnette-MD.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251106T121500
DTEND;TZID=America/New_York:20251106T131500
DTSTAMP:20260408T060921
CREATED:20250829T203319Z
LAST-MODIFIED:20251105T012941Z
UID:10000741-1762431300-1762434900@www.dupixentdiscussions.com
SUMMARY:Clinical Case Discussion: An Adolescent Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age  by Amy Spizuoco\, DO
DESCRIPTION:Join us for a program discussing a real-world case of an adolescent patient with moderate-to-severe atopic dermatitis (AD) and a treatment option that may help appropriate patients with Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=91675843349″]
URL:https://www.dupixentdiscussions.com/event/clinical-case-discussion-an-adolescent-patient-with-uncontrolled-moderate-to-severe-atopic-dermatitis-and-a-treatment-option-for-appropriate-patients-6-months-of-age-by-michael-cameron-md/
LOCATION:Virtual (Zoom)
CATEGORIES:Atopic Dermatitis (AD)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2023/05/Amy-Spizuoco-DO.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20251106T121500
DTEND;TZID=America/Denver:20251106T131500
DTSTAMP:20260408T060921
CREATED:20250829T203319Z
LAST-MODIFIED:20250919T211716Z
UID:10000742-1762431300-1762434900@www.dupixentdiscussions.com
SUMMARY:Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP) by Daniel Butler\, MD
DESCRIPTION:Learn more about the diagnosis and assessment of bullous pemphigoid (BP) including clinical manifestations\, key\nlaboratory investigations for diagnostic evaluation\, consensus-based recommendations and a treatment option for appropriate BP patients[gravityform id=”1″ field_values=”zoomid=98116325780″]
URL:https://www.dupixentdiscussions.com/event/pearls-and-common-challenges-for-the-diagnosis-of-bullous-pemphigoid-bp-by-daniel-butler-md/
LOCATION:Virtual (Zoom)
CATEGORIES:Bullous Pemphigoid (BP)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/06/Daniel-Butler-MD.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251110T121500
DTEND;TZID=America/New_York:20251110T131500
DTSTAMP:20260408T060921
CREATED:20250829T203328Z
LAST-MODIFIED:20250919T211724Z
UID:10000743-1762776900-1762780500@www.dupixentdiscussions.com
SUMMARY:Diagnosing and Assessing Chronic Spontaneous Urticaria (CSU) and a Treatment Option for Appropriate CSU Patients 12+ Years of Age by Leigh Ann Pansch\, NP
DESCRIPTION:Learn more about the diagnosis and assessment of chronic spontaneous urticaria (CSU)\, including its clinical manifestations\, diagnostic evaluation\, assessment scales\, and a treatment option for appropriate CSU patients 12+ years of age[gravityform id=”1″ field_values=”zoomid=91482439268″]
URL:https://www.dupixentdiscussions.com/event/diagnosing-and-assessing-chronic-spontaneous-urticaria-csu-and-a-treatment-option-for-appropriate-csu-patients-12-years-of-age-by-leigh-ann-pansch-np/
LOCATION:Virtual (Zoom)
CATEGORIES:Chronic Spontaneous Urticaria (CSU)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Leigh-Ann-Pansch-NP-ebg15G.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251110T121500
DTEND;TZID=America/Los_Angeles:20251110T131500
DTSTAMP:20260408T060921
CREATED:20250829T203328Z
LAST-MODIFIED:20250919T211733Z
UID:10000744-1762776900-1762780500@www.dupixentdiscussions.com
SUMMARY:DUPIXENT@ (dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Lakshi Aldredge\, NP
DESCRIPTION:Join us for a virtual discussion with an expert speaker and an adult patient with atopic dermatitis (AD) to Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=97111662107″]
URL:https://www.dupixentdiscussions.com/event/dupixent%c2%a8-dupilumab-patient-story-followed-by-a-treatment-option-for-appropriate-patients-with-certain-skin-diseases-driven-in-part-by-type-2-inflammation-by-lakshi-aldredge-np/
LOCATION:Virtual (Zoom)
CATEGORIES:Atopic Dermatitis (AD)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Lakshi-Aldredge-NP-MJutVB.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251112T121500
DTEND;TZID=America/New_York:20251112T131500
DTSTAMP:20260408T060921
CREATED:20250829T203328Z
LAST-MODIFIED:20250924T200016Z
UID:10000745-1762949700-1762953300@www.dupixentdiscussions.com
SUMMARY:DUPIXENT@(dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Sandri Johnson\, NP
DESCRIPTION:Join us for a virtual discussion with an expert speaker and an adult patient with prurigo nodularis (PN) to Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=99632311706″]
URL:https://www.dupixentdiscussions.com/event/dupixent%c2%a8-dupilumab-patient-story-followed-by-a-treatment-option-for-appropriate-patients-with-certain-skin-diseases-driven-in-part-by-type-2-inflammation-by-sandri-johnson-np/
LOCATION:Virtual (Zoom)
CATEGORIES:Prurigo Nodularis (PN)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Sandri-Johnson-NP-1jMtM8.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251112T121500
DTEND;TZID=America/Los_Angeles:20251112T131500
DTSTAMP:20260408T060921
CREATED:20250829T203329Z
LAST-MODIFIED:20250926T004311Z
UID:10000746-1762949700-1762953300@www.dupixentdiscussions.com
SUMMARY:Clinical Case Discussion: A Pediatric Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age  by Brittany Craiglow\, MD
DESCRIPTION:Join us for a program discussing a real-world case of a pediatric patient with moderate-to-severe atopic dermatitis (AD) and a treatment option that may help appropriate patients with Type 2 inflammation. [gravityform id=”1″ field_values=”zoomid=98410015485″]
URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-joe-gorelick-np/
LOCATION:Virtual (Zoom)
CATEGORIES:Atopic Dermatitis (AD)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2023/05/Brittany-Craiglow-MD.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251113T121500
DTEND;TZID=America/Los_Angeles:20251113T131500
DTSTAMP:20260408T060921
CREATED:20250829T203319Z
LAST-MODIFIED:20250926T005521Z
UID:10000740-1763036100-1763039700@www.dupixentdiscussions.com
SUMMARY:A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Raffi Tachdjian\, MD
DESCRIPTION:Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=97597438455″]
URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-raffi-tachdjian-md/
LOCATION:Virtual (Zoom)
CATEGORIES:Chronic Spontaneous Urticaria (CSU)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Raffi-Tachdjian-1-e1705692089736-CmAgJG.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260713T121500
DTEND;TZID=America/New_York:20260713T131500
DTSTAMP:20260408T060921
CREATED:20250829T203329Z
LAST-MODIFIED:20260403T212134Z
UID:10000747-1783944900-1783948500@www.dupixentdiscussions.com
SUMMARY:[Topic] by [Speaker]
DESCRIPTION:[Topic Description] \n[gravityform id=”1″ field_values=”zoomid=96558395763″]
URL:https://www.dupixentdiscussions.com/event/clinical-case-discussion-a-62-year-old-female-with-itchy-skin-lesions-could-it-be-pn-by-melissa-costner-md/
LOCATION:Virtual (Zoom)
CATEGORIES:Prurigo Nodularis (PN)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2024/04/aaaGeneric-Speaker.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20260713T121500
DTEND;TZID=America/Chicago:20260713T131500
DTSTAMP:20260408T060921
CREATED:20260407T012652Z
LAST-MODIFIED:20260407T012652Z
UID:10000750-1783944900-1783948500@www.dupixentdiscussions.com
SUMMARY:[Topic] by [Speaker]
DESCRIPTION:[Topic Description] \n[gravityform id=”1″ field_values=”zoomid=96558395763″]
URL:https://www.dupixentdiscussions.com/event/topic-by-speaker/
LOCATION:Virtual (Zoom)
CATEGORIES:Prurigo Nodularis (PN)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2024/04/aaaGeneric-Speaker.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260713T121500
DTEND;TZID=America/Los_Angeles:20260713T131500
DTSTAMP:20260408T060921
CREATED:20260407T012729Z
LAST-MODIFIED:20260407T012729Z
UID:10000751-1783944900-1783948500@www.dupixentdiscussions.com
SUMMARY:[Topic] by [Speaker]
DESCRIPTION:[Topic Description] \n[gravityform id=”1″ field_values=”zoomid=96558395763″]
URL:https://www.dupixentdiscussions.com/event/topic-by-speaker-2/
LOCATION:Virtual (Zoom)
CATEGORIES:Prurigo Nodularis (PN)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2024/04/aaaGeneric-Speaker.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260720T121500
DTEND;TZID=America/New_York:20260720T131500
DTSTAMP:20260408T060921
CREATED:20260407T012803Z
LAST-MODIFIED:20260407T012803Z
UID:10000752-1784549700-1784553300@www.dupixentdiscussions.com
SUMMARY:[Topic] by [Speaker]
DESCRIPTION:[Topic Description] \n[gravityform id=”1″ field_values=”zoomid=96558395763″]
URL:https://www.dupixentdiscussions.com/event/topic-by-speaker-3/
LOCATION:Virtual (Zoom)
CATEGORIES:Prurigo Nodularis (PN)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2024/04/aaaGeneric-Speaker.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260720T121500
DTEND;TZID=America/Los_Angeles:20260720T131500
DTSTAMP:20260408T060921
CREATED:20260407T012823Z
LAST-MODIFIED:20260407T012830Z
UID:10000753-1784549700-1784553300@www.dupixentdiscussions.com
SUMMARY:[Topic] by [Speaker]
DESCRIPTION:[Topic Description] \n[gravityform id=”1″ field_values=”zoomid=96558395763″]
URL:https://www.dupixentdiscussions.com/event/topic-by-speaker-4/
LOCATION:Virtual (Zoom)
CATEGORIES:Prurigo Nodularis (PN)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2024/04/aaaGeneric-Speaker.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260720T121500
DTEND;TZID=America/Los_Angeles:20260720T131500
DTSTAMP:20260408T060921
CREATED:20260407T012924Z
LAST-MODIFIED:20260407T012924Z
UID:10000754-1784549700-1784553300@www.dupixentdiscussions.com
SUMMARY:[Topic] by [Speaker]
DESCRIPTION:[Topic Description] \n[gravityform id=”1″ field_values=”zoomid=96558395763″]
URL:https://www.dupixentdiscussions.com/event/topic-by-speaker-5/
LOCATION:Virtual (Zoom)
CATEGORIES:Prurigo Nodularis (PN)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2024/04/aaaGeneric-Speaker.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260727T121500
DTEND;TZID=America/Los_Angeles:20260727T131500
DTSTAMP:20260408T060921
CREATED:20260407T013142Z
LAST-MODIFIED:20260407T013142Z
UID:10000755-1785154500-1785158100@www.dupixentdiscussions.com
SUMMARY:[Topic] by [Speaker]
DESCRIPTION:[Topic Description] \n[gravityform id=”1″ field_values=”zoomid=96558395763″]
URL:https://www.dupixentdiscussions.com/event/topic-by-speaker-6/
LOCATION:Virtual (Zoom)
CATEGORIES:Prurigo Nodularis (PN)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2024/04/aaaGeneric-Speaker.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260727T121500
DTEND;TZID=America/Los_Angeles:20260727T131500
DTSTAMP:20260408T060921
CREATED:20260407T013206Z
LAST-MODIFIED:20260407T013206Z
UID:10000756-1785154500-1785158100@www.dupixentdiscussions.com
SUMMARY:[Topic] by [Speaker]
DESCRIPTION:[Topic Description] \n[gravityform id=”1″ field_values=”zoomid=96558395763″]
URL:https://www.dupixentdiscussions.com/event/topic-by-speaker-7/
LOCATION:Virtual (Zoom)
CATEGORIES:Prurigo Nodularis (PN)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2024/04/aaaGeneric-Speaker.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260727T121500
DTEND;TZID=America/New_York:20260727T131500
DTSTAMP:20260408T060921
CREATED:20260407T013234Z
LAST-MODIFIED:20260407T013234Z
UID:10000757-1785154500-1785158100@www.dupixentdiscussions.com
SUMMARY:[Topic] by [Speaker]
DESCRIPTION:[Topic Description] \n[gravityform id=”1″ field_values=”zoomid=96558395763″]
URL:https://www.dupixentdiscussions.com/event/topic-by-speaker-8/
LOCATION:Virtual (Zoom)
CATEGORIES:Prurigo Nodularis (PN)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2024/04/aaaGeneric-Speaker.png
END:VEVENT
END:VCALENDAR